Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamlanivimab in hospitalized COVID-19 (ACTIV-3/TICO H1)
NCT05780268Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of bamlanivimab in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2020; status: completed.
02
Drugs
bamlanivimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05780268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780268.